Vivimed Labs Ltd Hits Upper Circuit Amid Strong Buying Pressure

Strong Buying Momentum Pushes Stock to Circuit Limit

On 09 Feb 2026, Vivimed Labs Ltd witnessed intense buying pressure that propelled the stock price to its upper circuit band of ₹7.57, with the last traded price (LTP) settling at ₹7.51. The stock recorded a day change of ₹0.3, translating to a 4.16% increase, outperforming its sector by 3.17% and the broader Sensex by 3.29%. This marked a significant rebound following five consecutive days of decline, signalling renewed investor interest.

The total traded volume stood at 3.20 lakh shares, reflecting active participation, although delivery volumes have notably declined. On 06 Feb, delivery volume was 1.87 lakh shares, down by 55.76% compared to the five-day average, indicating that short-term traders may be driving the current momentum rather than long-term holders.

Market Capitalisation and Liquidity Context

Vivimed Labs is classified as a micro-cap stock with a market capitalisation of ₹62.52 crore. Despite its small size, the stock demonstrated sufficient liquidity, with turnover reaching ₹0.24 crore on the day of the rally. Based on 2% of the five-day average traded value, the stock is liquid enough to accommodate trade sizes of approximately ₹0.01 crore, making it accessible for retail and institutional investors alike.

Technical Indicators and Moving Averages

Despite the strong intraday performance, Vivimed Labs continues to trade below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This suggests that while the stock has experienced a short-term bounce, the longer-term downtrend remains intact. Investors should exercise caution and monitor whether the stock can sustain this momentum and break above these key technical resistance levels.

Regulatory Freeze and Unfilled Demand

The stock’s upper circuit hit has triggered a regulatory freeze on fresh buy orders, a standard measure to curb excessive volatility. This freeze often results in unfilled demand accumulating on the buy side, which can fuel further price appreciation once the restrictions are lifted. Market participants are closely watching the order book to gauge the extent of latent buying interest.

Such circuit limits are designed to prevent erratic price movements, but they also highlight the stock’s heightened volatility and speculative interest. Investors should be mindful of the risks associated with trading stocks hitting upper circuits, especially in the micro-cap segment where liquidity and price swings can be more pronounced.

Mojo Score and Analyst Ratings

Vivimed Labs currently holds a Mojo Score of 24.0, categorised as a Strong Sell, reflecting concerns over its financial health and market performance. This rating was downgraded from Sell on 05 Feb 2026, indicating a deteriorating outlook. The company’s market cap grade is 4, consistent with its micro-cap status, and the score suggests caution for investors considering fresh exposure.

Despite the recent price surge, the fundamental and technical indicators remain weak, underscoring the need for a thorough risk-reward analysis before committing capital. The stock’s outperformance today may be a short-lived technical bounce rather than a sustained recovery.

Sector and Market Comparison

Vivimed Labs operates within the Pharmaceuticals & Drugs industry, a sector that has shown moderate gains with a 1.16% increase on the same day. The stock’s 4.58% one-day return significantly outpaced both the sector and the Sensex, which rose by 0.59%. This relative strength could attract momentum traders seeking short-term gains, but the broader sector fundamentals and company-specific challenges remain key considerations.

Investor Participation and Delivery Volumes

While the stock’s volume surged on the day of the rally, delivery volumes have fallen sharply, indicating that fewer investors are holding shares for the long term. This decline in delivery volume by 55.76% compared to the five-day average suggests that the recent buying may be driven by speculative traders rather than institutional accumulation.

Such patterns often precede volatile price action, and investors should watch for confirmation of sustained buying interest or a reversal in delivery trends to assess the stock’s true momentum.

Outlook and Investor Considerations

Vivimed Labs’ upper circuit hit reflects a momentary surge in demand, but the stock’s fundamental challenges and technical weaknesses remain significant. Investors should weigh the risks of trading a micro-cap stock with a Strong Sell rating and limited institutional support. The current rally may offer short-term trading opportunities, but a sustained recovery will require improved financial performance and positive sector dynamics.

Market participants are advised to monitor key technical levels, delivery volumes, and regulatory developments closely. The stock’s liquidity profile supports moderate trading activity, but volatility is likely to persist given the unfilled demand and regulatory freeze in place.

In summary, while Vivimed Labs Ltd’s price action today is noteworthy, a cautious approach is warranted until clearer signs of a turnaround emerge.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →